PerkinElmer与哈勃,为人类打磨一双慧眼
在历史长河中,人类对于头顶上这片星空的探索从公元前开始就从未停止过。古希腊先人用自己丰富的想象力和浪漫情怀为夜晚的星空划分出一个个星座,寄寓着一个个动人的神话故事。而现代人类早已不满足于用想象力去定义这浩瀚的宇宙,人们渴望着用自己的眼睛更真实地感知我们生活的宇宙空间。
We're Moving to
The content you are trying to access has moved to new site. Explore, discover (and in certain contries, buy) our products and services on our new website. Click to visit now or you will be automatically redirected.
to view non-migrated solutions
The European ScreeningPort (ESP) is a public-private partnership that works for academic institutions to create and operate drug discovery programs that address novel therapeutic targets. Their key competency lies in early stage (target-to-lead) small molecule discovery, using a screening approach.
The ESP's state-of-the-art screening infrastructure includes access to up to 400,000 "ready-to-screen" compounds designed to address a range of target classes including those with specific relevance to neurological disease and protein::protein interactions like those associated with intracellular signaling pathways.
Promising results on the causes of disease, generated during basic research, require specific processes in order to accelerate the translation of these results into new therapeutics. Until recently, those processes have only been available to the pharmaceutical industry.
In addition, researchers often use synthetic peptides or engineered cell lines as they are easier to handle. However, they bear little relation to the underlying disease biology compared to the physiologically relevant results that can be obtained with native protein substrates or primary cells.
"Our infrastructure is based around the fully integrated PerkinElmer robotic cell::explorer® automated high content screening system, which forms the centerpiece of the ESPs in-vitro screening facility."
To aid the acceleration of promising results into therapeutics, the ESP's core infrastructure is based around the fully-integrated PerkinElmer robotic cell::explorer® automated high content screening system. The system handles 96 to 1536 well microplates with integrated nanoliter-scale dispensing, industry standard liquid handling for larger volumes, robust plate handling and sensitive multi-mode optical based readouts. This infrastructure allows the ESP to provide mainstream, physiologically relevant optical assay readouts, commonly found within the pharmaceutical industry, to its academic customers, including high content imaging, AlphaScreen® assays and time-resolved FRET.
Approximately 40 percent of the academic targets investigated by ESP involve hit finding to identify small molecules that selectively disrupt protein::protein or protein::DNA interactions. PerkinElmer's AlphaScreen technology is used to identify hits in these target classes, and a "toolbox" of donor and acceptor bead combinations rapidly identifies optimal assay formats.
To follow up on hits, the ESP uses high content imaging, including PerkinElmer's confocal Opera® High Content Screening System, to directly visualize cellular processes and interactions, and to localize and quantify individual protein interactions and modifications.
ESP gives major German academic institutions, as well as academics in Canada, The Netherlands, New Zealand, Switzerland and the United Kingdom, a pathway to physiologically relevant results. Typical projects integrate medicinal chemistry insight with in-vitro and in-silico structural and disease biology knowledge to help researchers identify which molecules have the best chance of being translated from the laboratory to the clinical setting.
For Research use only. Not for use in diagnostic procedures.
在历史长河中,人类对于头顶上这片星空的探索从公元前开始就从未停止过。古希腊先人用自己丰富的想象力和浪漫情怀为夜晚的星空划分出一个个星座,寄寓着一个个动人的神话故事。而现代人类早已不满足于用想象力去定义这浩瀚的宇宙,人们渴望着用自己的眼睛更真实地感知我们生活的宇宙空间。
珀金埃尔默对创新的承诺是建立在公司的科学家和研究人员的伟大工作之上的,是他们的研究成果建立了珀金埃尔默在人类和环境健康领域的市场领先优势。
Milano-Bicocca大学环境科学系的Giovanni Baccolo博士和他的同事研究分析南极冰芯样品,重点在于分析包裹在冰中的大气矿物颗粒,俗称“尘埃”。
我是来自珀金埃尔默的ChemDraw,我为化学绘图代言!
在历史性的卡西尼号太空船任务中珀金埃尔默扮演的角色。